Proteintech

Proteintech Group is a multinational biotechnology company with offices based in the USA (Chicago IL), Europe (Manchester, UK) and China (Wuhan). Founded as a start-up company in Chicago in 2002, it supplies polyclonal and monoclonal antibodies to the medical and life science research community.

Proteintech produces all of its antibodies therefore does not ‘resell’ antibodies, i.e. it does not source its antibodies from other companies. Proteintech currently have 11,000 pre-made primary antibodies for sale.[1]

Proteintech antibodies used in research

Proteintech Group’s antibodies have been successful in several research areas. For example, the antibody against TAR DNA-binding protein 43 has featured in many publications investigating its role in many neuropathologies including: ALS,[2][3] FTLD,[4] Alzheimer's disease,.[5] Parkinson's disease[6][7] Lewy body disease[8] Huntington's Disease[9] and Machado-Joseph disease[10] Proteintech was also the first company to provide a commercially available FKBPL antibody. This has been most notably used in a study to determine the response of breast cancer patients to the drug Tamoxifen.[11]

References

  1. ↑ http://www.ptglab.com
  2. ↑ Neumann, M., et al., Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science, 2006. 314(5796): p. 130-3.
  3. ↑ Maruyama, H., et al., Mutations of optineurin in amyotrophic lateral sclerosis. Nature, 2010. 465(7295): p. 223-6.
  4. ↑ Roeber, S., et al., TDP-43-negative FTLD-U is a significant new clinico-pathological subtype of FTLD. Acta Neuropathol, 2008. 116(2): p. 147-57.
  5. ↑ Hu, W.T., et al., Temporal lobar predominance of TDP-43 neuronal cytoplasmic inclusions in Alzheimer disease. Acta Neuropathol, 2008. 116(2): p. 215-20
  6. ↑ Chanson, J.B., et al., TDP43-positive intraneuronal inclusions in a patient with motor neuron disease and Parkinson's disease. Neurodegener Dis, 2010. 7(4): p. 260-4.
  7. ↑ Burack, M.A., et al., In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. Neurology, 2010. 74(1): p. 77-84.
  8. ↑ Lin, W.L., M. Castanedes-Casey, and D.W. Dickson, Transactivation response DNA-binding protein 43 microvasculopathy in frontotemporal degeneration and familial Lewy body disease. J Neuropathol Exp Neurol, 2009. 68(11): p. 1167-76.
  9. ↑ Schwab, C., et al., Colocalization of transactivation-responsive DNA-binding protein 43 and huntingtin in inclusions of Huntington disease. J Neuropathol Exp Neurol, 2008. 67(12): p. 1159-65.
  10. ↑ Tan, C.F., et al., Selective occurrence of TDP-43-immunoreactive inclusions in the lower motor neurons in Machado-Joseph disease. Acta Neuropathol, 2009. 118(4): p. 553-60.
  11. ↑ McKeen, H.D., et al., FKBPL regulates estrogen receptor signaling and determines response to endocrine therapy. Cancer Res, 2010. 70(3): p. 1090-100.

External links

This article is issued from Wikipedia - version of the Tuesday, January 07, 2014. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.